Aktis Oncology, Inc. Common stock
Veridion Score
Composite trend over time
Why is AKTS moving today?
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for AKTS.
AKTS insider activity
Aktis Oncology, Inc. Common stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for AKTS.
AKTS contract awards, year to date.
Public federal awards linked to this ticker.
AKTS lobbying filings, year to date.
Registered lobbying filings matched to Aktis Oncology, Inc. Common stock.